Condition: Advanced Malignant Solid Neoplasm · RAS Mutation · Lung Cancer · Sponsor: RasCal Therapeutics, Inc.
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
This description comes directly from the study's public registry record.
Michael Mann, MD · 310-498-7171 · clinicaltrials@rascaltherapeutics.com
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology | Los Angeles, California, United States | Recruiting |
| Sarah Cannon, SCRI Oncology Partners - Health One | Denver, Colorado, United States | Recruiting |
| Sarah Cannon, SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04678648